NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 184)
Posted On: 12/13/2017 7:11:43 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Granted U.S. Patent Regarding DehydraTECH™ Technology
Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) reported this morning that it has been granted a patent from the United States Patent and Trademark Office ("USPTO"
increasing its intellectual property (“IP”) hold of its DehydraTECH™ technology. The newly-issued patent covers the use of DehydraTECH™ technology as a delivery platform for a broad range of Active Pharmaceutical Ingredients ("APIs" including all cannabinoids, fat soluble vitamins, non-steroidal anti-inflammatory pain medications ("NSAIDs" , and nicotine. In addition, Lexaria continues to advance all of its other patent applications worldwide. “This ground-breaking, patented IP builds a foundation for new business opportunities in 2018 including what could be the world's first nicotine edibles for the smokeless tobacco industry or improved new products for NSAID-derived pain management, as well as in the rapidly growing cannabis market," Lexaria Bioscience chief executive officer Chris Bunka stated in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) reported this morning that it has been granted a patent from the United States Patent and Trademark Office ("USPTO"
increasing its intellectual property (“IP”) hold of its DehydraTECH™ technology. The newly-issued patent covers the use of DehydraTECH™ technology as a delivery platform for a broad range of Active Pharmaceutical Ingredients ("APIs" including all cannabinoids, fat soluble vitamins, non-steroidal anti-inflammatory pain medications ("NSAIDs" , and nicotine. In addition, Lexaria continues to advance all of its other patent applications worldwide. “This ground-breaking, patented IP builds a foundation for new business opportunities in 2018 including what could be the world's first nicotine edibles for the smokeless tobacco industry or improved new products for NSAID-derived pain management, as well as in the rapidly growing cannabis market," Lexaria Bioscience chief executive officer Chris Bunka stated in the news release. Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼